Why the study?
Clopidogrel has broad interindividual response variability linked to CYP2C19 genetic variations, while potent alternatives increase bleeding risk, prompting the need to appraise genetic testing to guide P2Y12 inhibitor selection.
Does genetic testing-guided selection of P2Y12 inhibitors improve outcomes in patients undergoing PCI?
Population
Patients undergoing PCI
Design
Review
Key result
Genetic-guided selection of antiplatelet therapy in patients undergoing PCI represents a promising precision medicine strategy for escalating or de-escalating P2Y12 inhibiting therapy.
Authors
Loading...
Supports genotype-guided P2Y12 inhibitor selection to balance ischemic and bleeding risks;.
Does genetic testing-guided selection of P2Y12 inhibitors improve outcomes in patients undergoing PCI?
Integrating genetic testing with clinical and procedural variables offers a promising precision medicine approach for selecting antiplatelet therapy in PCI patients.
Galli et al. (2021) conducted a review in Patients undergoing percutaneous coronary intervention (PCI). Genetic testing to guide selection of platelet P2Y12 inhibitors was evaluated. Genetic-guided selection of antiplatelet therapy in patients undergoing PCI represents a promising precision medicine strategy for escalating or de-escalating P2Y12 inhibiting therapy.